Biao Hong

507 total citations
19 papers, 312 citations indexed

About

Biao Hong is a scholar working on Molecular Biology, Cancer Research and Genetics. According to data from OpenAlex, Biao Hong has authored 19 papers receiving a total of 312 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 11 papers in Cancer Research and 6 papers in Genetics. Recurrent topics in Biao Hong's work include Glioma Diagnosis and Treatment (6 papers), Cancer-related molecular mechanisms research (5 papers) and Cancer, Hypoxia, and Metabolism (4 papers). Biao Hong is often cited by papers focused on Glioma Diagnosis and Treatment (6 papers), Cancer-related molecular mechanisms research (5 papers) and Cancer, Hypoxia, and Metabolism (4 papers). Biao Hong collaborates with scholars based in China, United States and United Kingdom. Biao Hong's co-authors include Chunsheng Kang, Qixue Wang, Jixing Zhao, Xiaoteng Cui, Menglin Xiao, Yanli Tan, Shixue Yang, Kaikai Yi, Can Xu and Chuan Fang and has published in prestigious journals such as Journal of Controlled Release, Frontiers in Immunology and Cancer Letters.

In The Last Decade

Biao Hong

15 papers receiving 312 citations

Peers

Biao Hong

GENET

IMMUN

Shixue Yang China

Amber B. Jones United States

Angana Biswas India

Alice Boissard France

Rebeca Piatniczka Iglesia Brazil

Lynette M. Phillips United States

Cristina Zahonero Spain

Jingchao Zhou China

Nastaran Mohammadi Ghahhari Iran

Shixue Yang China

Biao Hong

204 ×1.0

136 ×0.9

70 ×0.9

GENET

43 ×1.0

IMMUN

42 ×1.2

Citations per year, relative to Biao Hong Biao Hong (= 1×) peers Shixue Yang

Countries citing papers authored by Biao Hong

Since Specialization

Citations

This map shows the geographic impact of Biao Hong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Biao Hong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Biao Hong more than expected).

Fields of papers citing papers by Biao Hong

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Biao Hong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Biao Hong. The network helps show where Biao Hong may publish in the future.

Co-authorship network of co-authors of Biao Hong

This figure shows the co-authorship network connecting the top 25 collaborators of Biao Hong. A scholar is included among the top collaborators of Biao Hong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Biao Hong. Biao Hong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Hong, Biao, Shixue Yang, Xing Cui, et al.. (2025). Linagliptin synergizes with cPLA2 inhibition to enhance temozolomide efficacy by interrupting DPP4-mediated EGFR stabilization in glioma. Acta Pharmaceutica Sinica B. 15(7). 3632–3645.

Zhan, Qi, Kaikai Yi, Shixue Yang, et al.. (2025). LPC-engineered liposomes activate transcytosis for paclitaxel brain delivery and potentiation of TTFields/TMZ via TALECT regimen in glioblastoma. Theranostics. 16(5). 2249–2268.

Cheng, Chao, Xing Cui, Qi Zhan, et al.. (2025). ADAM12 promotes temozolomide resistance in glioblastoma by activating the TNF-α - NF-κB pathway. Cancer Letters. 620. 217684–217684.

Hong, Biao, Yuan Xue, Bowen Shen, et al.. (2025). Bioinspired prussian blue nanopesticides with triple-stimuli-responsive gates for ecology-adaptive pest management. Journal of Controlled Release. 386. 114162–114162.

Yang, Eryan, Biao Hong, Yunfei Wang, et al.. (2024). EPIC-0628 abrogates HOTAIR/EZH2 interaction and enhances the temozolomide efficacy via promoting ATF3 expression and inhibiting DNA damage repair in glioblastoma. Cancer Letters. 588. 216812–216812. 10 indexed citations

Zhao, Jixing, Xiaoteng Cui, Zhan Qi, et al.. (2024). CRISPR-Cas9 library screening combined with an exosome-targeted delivery system addresses tumorigenesis/TMZ resistance in the mesenchymal subtype of glioblastoma. Theranostics. 14(7). 2835–2855. 21 indexed citations

Xiao, Menglin, Xiaoteng Cui, Jixing Zhao, et al.. (2024). Deep‐targeted gene sequencing reveals ARID1A mutation as an important driver of glioblastoma. CNS Neuroscience & Therapeutics. 30(4). e14698–e14698. 6 indexed citations

Yang, Shixue, Qi Zhan, Xiaoteng Cui, et al.. (2024). HIF1α/ATF3 partake in PGK1 K191/K192 succinylation by modulating P4HA1/succinate signaling in glioblastoma. Neuro-Oncology. 26(8). 1405–1420. 24 indexed citations

Cui, Xiaoteng, Jixing Zhao, Guanzhang Li, et al.. (2023). Blockage of EGFR/AKT and mevalonate pathways synergize the antitumor effect of temozolomide by reprogramming energy metabolism in glioblastoma. Cancer Communications. 43(12). 1326–1353. 22 indexed citations

10.

Lei, Xin, Yanli Tan, Xiaoteng Cui, et al.. (2023). EPIC-0307-mediated selective disruption of PRADX–EZH2 interaction and enhancement of temozolomide sensitivity to glioblastoma via inhibiting DNA repair and MGMT. Neuro-Oncology. 25(11). 1976–1988. 12 indexed citations

11.

Hong, Biao, Eryan Yang, Xiaoteng Cui, et al.. (2023). EPIC-1042 as a potent PTRF/Cavin1–caveolin-1 interaction inhibitor to induce PARP1 autophagic degradation and suppress temozolomide efflux for glioblastoma. Neuro-Oncology. 26(1). 100–114. 10 indexed citations

12.

Xu, Can, Jixing Zhao, Jia L. Song, et al.. (2022). lncRNA PRADX is a Mesenchymal Glioblastoma Biomarker for Cellular Metabolism Targeted Therapy. Frontiers in Oncology. 12. 888922–888922. 13 indexed citations

13.

Yang, Eryan, Lin Wang, Weili Jin, et al.. (2022). PTRF/Cavin-1 enhances chemo-resistance and promotes temozolomide efflux through extracellular vesicles in glioblastoma. Theranostics. 12(9). 4330–4347. 27 indexed citations

14.

Yang, Shixue, Jixing Zhao, Xiaoteng Cui, et al.. (2022). TCA-phospholipid-glycolysis targeted triple therapy effectively suppresses ATP production and tumor growth in glioblastoma. Theranostics. 12(16). 7032–7050. 36 indexed citations

15.

Yi, Kaikai, Xiaoteng Cui, Xing Liu, et al.. (2022). PTRF/Cavin-1 as a Novel RNA-Binding Protein Expedites the NF-κB/PD-L1 Axis by Stabilizing lncRNA NEAT1, Contributing to Tumorigenesis and Immune Evasion in Glioblastoma. Frontiers in Immunology. 12. 802795–802795. 26 indexed citations

16.

Zhao, Jixing, Shixue Yang, Xiaoteng Cui, et al.. (2022). A novel compound EPIC-0412 reverses temozolomide resistance via inhibiting DNA repair/MGMT in glioblastoma. Neuro-Oncology. 25(5). 857–870. 43 indexed citations

17.

Chen, Peirong, Jianmin Xiao, Biao Hong, et al.. (2021). Highly sensitive T ₁ – T ₂ dual-mode MRI probe based on ultra-small gadolinium oxide-decorated iron oxide nanocrystals. Biomedical Materials. 16(4). 44104–44104. 6 indexed citations

18.

Xiao, Jianmin, Ke Zhou, Hui Chen, et al.. (2021). A nanoselenium-coating biomimetic cytomembrane nanoplatform for mitochondrial targeted chemotherapy- and chemodynamic therapy through manganese and doxorubicin codelivery. Journal of Nanobiotechnology. 19(1). 227–227. 11 indexed citations

19.

Zhao, Jixing, Weili Jin, Kaikai Yi, et al.. (2021). Combination LSD1 and HOTAIR-EZH2 inhibition disrupts cell cycle processes and induces apoptosis in glioblastoma cells. Pharmacological Research. 171. 105764–105764. 45 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact